Other targets of interest for AML that show minimal or no expression on HSPCs, and therefore may preclude the use of allo-HSCT, include ILT3 (LILRB4), CD44v6, folate receptor β, and GPR78 (Table 3).121. This evidence concerns the gene LILRB4 and acute myeloid leukemia.